5 not yet recruiting, 1 recruiting, 1 withdrawn. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Not yet recruiting 4, Recruiting 1, Withdrawn 1 |
| Phase 2 | 3 | Not yet recruiting 2, Withdrawn 1 |
Follow C-CAR168: new trials by email Literature Review of C-CAR168 trials Research Report on C-CAR168
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis | Phase 1 | Not yet recruiting | AbelZeta Inc. | 12 | 2027-03-01 | 2026-10-13 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | AbelZeta Inc. | 119 | 2027-02-01 | 2026-10-13 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy C-CAR168 - Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE) | Phase 2 | Not yet recruiting | AbelZeta Inc. | 50 | 2026-09-30 | 2026-10-13 |
| C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease C-CAR168 - Lupus Nephritis (LN) | Phase 1 / Phase 2 | Withdrawn | AbelZeta Inc. | 2026-07-01 | 2026-07-16 | |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 1 | Not yet recruiting | Huashan Hospital | 15 | 2026-02-01 | 2026-01-15 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM) | Phase 1 | Recruiting | RenJi Hospital | 30 | 2024-03-20 | 2025-07-25 |
Lupus Erythematosus, Systemic (4) · Multiple Sclerosis (4) · Neuromyelitis Optica (3) · Scleroderma, Systemic (3) · Autoimmune Diseases (2) · Lupus Nephritis (2) · Myasthenia Gravis (2) · Autoimmune Diseases of the Nervous System (1) · Multiple Sclerosis, Chronic Progressive (1) · Scleroderma, Diffuse (1) · Stiff-Person Syndrome (1)
AbelZeta Inc. (4) · Huashan Hospital (1) · RenJi Hospital (1) · The Affiliated Hospital of Qingdao University (1)
United States (3) · China (2)
Yihong Yao, PhD (2) · Nan Shen, MD & PhD (1) · Scott Antonia (1) · Scott Antonia, MD, PhD (1)